AstraZeneca's Phase III Trial of First-in-Class AKT Inhibitor Truqap Fails to Meet Primary Endpoints in Triple-Negative Breast Cancer

On June 18, AstraZeneca's official website disclosed that its first-in-class AKT inhibitor Truqap showed results in a Phase III clinical trial involving the full population or subgroup patients with specific biomarker alterations.Combination Chemotherapy as First-Line Treatment for Triple-Negative Breast Cancer (TNBC) Fails to Meet Dual Primary Endpoints of Survival.

AstraZeneca stated that the safety profile of the Truqap combination is generally consistent with the known characteristics of each drug, with no new safety signals identified. Full trial details will be shared "at the appropriate time." In November last year,Truqap Approved by FDA for Treatment of HR-Positive, HER2-Negative Advanced or Metastatic Breast CancerAstraZeneca has always placed great importance on this drug.

The AKT target has been attempted by several multinational pharmaceutical giants, including GlaxoSmithKline, Merck, and Eli Lilly, but so far, only AstraZeneca's Truqap has successfully reached the market.AKT Target: A "Treasure Molecule" Spanning Two Major Indications - Prostate Cancer and Breast Cancer, with huge market potential, and some analysis institutions believe that the peak sales of Truqap can reach 3.8 billion US dollars.

Apart from AstraZeneca, only a handful of companies globally have been able to advance AKT-targeted drugs into Phase III clinical trials.In China, companies such as Zhengda Tianqing, HaiChang Biotech, and Laikang Pharmaceutical have made arrangements.

Jian Shi Ju learned that AstraZeneca is developing other clinical directions for Truqap, including a clinical trial of triplet therapy as a first-line treatment for locally advanced, inoperable, or metastatic HR-positive, HER2-negative breast cancer. In addition, two trials for Truqap in prostate cancer treatment have already been initiated.